Klotz L - Search Results

1

Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets.

Gross CC, Schulte-Mecklenbeck A, Hanning U, Posevitz-Fejfár A, Korsukewitz C, Schwab N, Meuth SG, Wiendl H, Klotz L. Gross CC, et al. Among authors: klotz l. Mult Scler. 2017 Jun;23(7):1025-1030. doi: 10.1177/1352458516662726. Epub 2016 Aug 1. Mult Scler. 2017. PMID: 27481205

2

The variant methylenetetrahydrofolate reductase c.1298A>C (p.E429A) is associated with multiple sclerosis in a German case-control study.

Klotz L, Farkas M, Bain N, Keskitalo S, Semmler A, Ineichen B, Jelcic J, Klockgether T, Kölsch H, Weller M, Linnebank M. Klotz L, et al. Neurosci Lett. 2010 Jan 14;468(3):183-5. doi: 10.1016/j.neulet.2009.10.057. Epub 2009 Oct 23. Neurosci Lett. 2010. PMID: 19854238 Free article.

3

Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.

Klotz L, Meuth SG, Wiendl H. Klotz L, et al. Clin Immunol. 2012 Jan;142(1):25-30. doi: 10.1016/j.clim.2011.04.006. Epub 2011 Apr 15. Clin Immunol. 2012. PMID: 21550857 Review.

4

[Diagnosis of multiple sclerosis 2010 revision of the McDonald criteria].

Klotz L, Gold R, Hemmer B, Korn T, Zipp F, Hohlfeld R, Kieseier BC, Wiendl H. Klotz L, et al. Nervenarzt. 2011 Oct;82(10):1302-9. doi: 10.1007/s00115-011-3283-x. Nervenarzt. 2011. PMID: 21681517 German. No abstract available.

5

Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ.

Hucke S, Floßdorf J, Grützke B, Dunay IR, Frenzel K, Jungverdorben J, Linnartz B, Mack M, Peitz M, Brüstle O, Kurts C, Klockgether T, Neumann H, Prinz M, Wiendl H, Knolle P, Klotz L. Hucke S, et al. Among authors: klotz l. Brain. 2012 May;135(Pt 5):1586-605. doi: 10.1093/brain/aws058. Epub 2012 Mar 24. Brain. 2012. PMID: 22447120

6

Monoclonal antibodies in neuroinflammatory diseases.

Klotz L, Wiendl H. Klotz L, et al. Expert Opin Biol Ther. 2013 Jun;13(6):831-46. doi: 10.1517/14712598.2013.767329. Epub 2013 Mar 22. Expert Opin Biol Ther. 2013. PMID: 23521026 Review.

7

[Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies].

Klotz L, Meuth SG, Kieseier B, Wiendl H. Klotz L, et al. Nervenarzt. 2013 Aug;84(8):984-94. doi: 10.1007/s00115-013-3814-8. Nervenarzt. 2013. PMID: 23793409 Clinical Trial. German.

8

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.

Luessi F, Kraus S, Trinschek B, Lerch S, Ploen R, Paterka M, Roberg T, Poisa-Beiro L, Klotz L, Wiendl H, Bopp T, Jonuleit H, Jolivel V, Zipp F, Witsch E. Luessi F, et al. Among authors: klotz l. Mult Scler. 2015 Dec;21(14):1811-22. doi: 10.1177/1352458515574895. Epub 2015 Mar 2. Mult Scler. 2015. PMID: 25732840

9

Fingolimod treatment promotes regulatory phenotype and function of B cells.

Grützke B, Hucke S, Gross CC, Herold MV, Posevitz-Fejfar A, Wildemann BT, Kieseier BC, Dehmel T, Wiendl H, Klotz L. Grützke B, et al. Among authors: klotz l. Ann Clin Transl Neurol. 2015 Feb;2(2):119-30. doi: 10.1002/acn3.155. Epub 2015 Jan 16. Ann Clin Transl Neurol. 2015. PMID: 25750917 Free PMC article.

10

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Klotz L, Grützke B, Eveslage M, Deppe M, Gross CC, Kirstein L, Posevitz-Fejfar A, Schneider-Hohendorf T, Schwab N, Meuth SG, Wiendl H. Klotz L, et al. BMC Neurol. 2015 Jun 23;15:96. doi: 10.1186/s12883-015-0354-9. BMC Neurol. 2015. PMID: 26099927 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,040 results

Search Page